404 results If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug. The ECJ’s ruling in Servier: Never Settle For Less Patent settlement agreements between originator pharmaceutical companies and generics manufacturers are a risky business. Originator medicine company Servier and five generic companies rolled the dice and the ECJ largely confirmed their antitrust fines. Commission steers market definition to the 21st century Companies have a new and improved tool for the competitive assessment of their conduct and intended acquisitions. The European Commission has updated its guidance on how to define relevant markets for the purpose of EU competition law enforcement. Selectie nieuwe prejudiciële vragen over consumentenrecht Hier vindt u een selectie van nieuwe prejudiciële vragen over het consumentenrecht uit 2023. Sélection de nouvelles questions préjudicielles en matière de droit de la consommation Veuillez trouver ici une sélection de nouvelles questions préjudicielles en matière du droit de la consommation en 2023. Omnibus-ontwikkelingen: aanpassing van de CSRD en eerste stappen herziening van ESRS Op 26 februari 2025 heeft de Europese Commissie het Vereenvoudigingspakket Omnibus I (Omnibus) gepubliceerd. Stibbe advises Seven2 Stibbe advised Seven2 on the acquisition of a majority stake in Zwart Techniek. Navigating SFDR 2.0: Unofficial Consolidated Text of the Commission’s Proposal Following the European Commission’s proposal of 20 November 2025 to amend the SFDR, Stibbe has prepared a non-official consolidated version of SFDR 2.0 to help interested persons navigate the proposed EU sustainable finance legal framework. Pagination Previous page Page 20 Page 21 Page 22 Current page 23
If you have nothing nice to say…Teva fined heavily for abusive conduct Dominant pharma companies had better watch their words and use the patent system wisely. Pharma company Teva was fined EUR 462.6 million for disparagement and ‘divisional gaming’ to delay market entry and hinder the uptake of a competing drug.
The ECJ’s ruling in Servier: Never Settle For Less Patent settlement agreements between originator pharmaceutical companies and generics manufacturers are a risky business. Originator medicine company Servier and five generic companies rolled the dice and the ECJ largely confirmed their antitrust fines.
Commission steers market definition to the 21st century Companies have a new and improved tool for the competitive assessment of their conduct and intended acquisitions. The European Commission has updated its guidance on how to define relevant markets for the purpose of EU competition law enforcement.
Selectie nieuwe prejudiciële vragen over consumentenrecht Hier vindt u een selectie van nieuwe prejudiciële vragen over het consumentenrecht uit 2023.
Sélection de nouvelles questions préjudicielles en matière de droit de la consommation Veuillez trouver ici une sélection de nouvelles questions préjudicielles en matière du droit de la consommation en 2023.
Omnibus-ontwikkelingen: aanpassing van de CSRD en eerste stappen herziening van ESRS Op 26 februari 2025 heeft de Europese Commissie het Vereenvoudigingspakket Omnibus I (Omnibus) gepubliceerd.
Stibbe advises Seven2 Stibbe advised Seven2 on the acquisition of a majority stake in Zwart Techniek.
Navigating SFDR 2.0: Unofficial Consolidated Text of the Commission’s Proposal Following the European Commission’s proposal of 20 November 2025 to amend the SFDR, Stibbe has prepared a non-official consolidated version of SFDR 2.0 to help interested persons navigate the proposed EU sustainable finance legal framework.